Ensign Peak Advisors
JBIO

Ensign Peak Advisors’s Jade Biosciences JBIO Stock Holding History

Ensign Peak Advisors’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-7,493
Closed -$7.75M – 1715
2024
Q1 		$7.75M Buy
7,493
+4,000
+115% +$3.06M 0.01% 513
2023
Q4 		$2.77M Buy
3,493
+3,064
+714% +$1.56M 0.01% 792
2023
Q3 		$204K Hold
429
– – ﹤0.01% 1725
2023
Q2 		$257K Hold
429
– – ﹤0.01% 1726
2023
Q1 		$303K Sell
429
-177
-29% -$147K ﹤0.01% 1713
2022
Q4 		$621K Buy
+606
New +$440K ﹤0.01% 1536

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ensign Peak Advisors's JBIO Position: Q2 2024 in Review

Ensign Peak Advisors sold out of Jade Biosciences (JBIO) in Q2 2024, closing a stake of 7,493 shares — an estimated $7.75M sold.

Ensign Peak Advisors first reported a position in JBIO in Q4 2022 and held it in 6 quarters. The position peaked at $7.75M in Q1 2024. 80 funds tracked by Wall St. Rank hold JBIO as of Q2 2024.

  • Ensign Peak Advisors reported no remaining Jade Biosciences position as of Q2 2024 after selling out during the quarter.
  • Ensign Peak Advisors sold 7,493 Jade Biosciences shares in Q2 2024, an estimated $7.75M.
  • Ensign Peak Advisors first reported a position in Jade Biosciences in Q4 2022 and held it in 6 quarters.
  • Ensign Peak Advisors's Jade Biosciences position peaked at $7.75M in Q1 2024.
  • 80 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2024.

Based on Ensign Peak Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.